Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Molecular subclusters across the continuum of myelodysplastic neoplasms and acute myeloid leukaemia define distinct clinical entities

View Full Paper
Ask AI
Bookmark
Share

Authors

SHSuzan van Hoppe

Discussion

Loading...

Member takes

Overview

Analysis reveals distinct molecular subgroups in myelodysplastic neoplasms and acute myeloid leukaemia, suggesting varied therapeutic interventions using mutation data.

Key Points

  • Distinct molecular subgroups impact treatment outcomes across acute myeloid leukaemia and myelodysplastic neoplasms.
  • A total of 1007 patients provided genetic data for analysis using Bernoulli distributions, revealing significant cluster differences.
  • Modeling through the Akaike Information Criterion identified clusters linked to overall survival and disease progression.
  • The findings support classifications that may improve targeted therapies and highlight the need for validation in future studies.

Cite This Study

Suzan van Hoppe (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d855https://doi.org/10.1182/blood-2025-3869
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Deciphering clonal progression in MDS via longitudinal sequencing2025
  2. 2Which molecular patterns of high-risk myeloid malignancies are concordantly identified using two machine learning algorithms?2025
  3. 3Longitudinal genomic and cytogenetic dynamics in myelodysplastic syndromes (MDS): Insights into clonal evolution and disease progression2025
  4. 4Unifying the classification of acute myeloid leukemia, myelodysplasia-related: A multi-institutional experience2025 · 1 citations
  5. 5Myelodysplastic/myeloproliferative overlap neoplasms: Clinicopathological features, treatment strategies, and outcomes — a UK multicentre cohort Study2025